Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre-Reference-Cited by-同舟云学术

Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre

Published:2018-07 Issue: Volume:390 Page:67-74
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Morano Alessandra,Fattouch Jinane,Albini Mariarita,Casciato Sara,Fanella Martina,Basili Luca Manfredi,Viganò Alessandro,Manfredi Mario,Giallonardo Anna Teresa,Di Bonaventura Carlo

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology

Reference29 articles.

1. Early identification of refractory epilepsy;Kwan;N. Engl. J. Med.,2000

2. Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy;Citraro;Expert Opin. Ther. Targets,2014

3. Perampanel as adjunctive therapy in patients with partial-onset seizures;Plosker;CNS Drugs,2012

4. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives;Di Bonaventura;Expert. Opin. Pharmacother.,2017

5. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304;French;Neurology,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring of perampanel: Clinical utility and impact of co-medication on pharmacokinetic variability;Heliyon;2024-01

2. Five-Year Retention of Perampanel and Polytherapy Patterns: 328 Patients From a Single Center in South Korea;Journal of Clinical Neurology;2023

3. Sleep–wake cycle and daytime sleepiness in patients with epilepsy after initiating perampanel as adjunctive therapy;Neurological Sciences;2022-12-08

4. Efficacy and safety of perampanel in epilepsy: A systematic review and meta-analysis of randomised controlled trials;Seizure;2022-11

5. The real-world effectiveness and safety of perampanel in Europe: A scoping review;Epilepsy & Behavior;2022-09